Peripheral blood CD4/CD19 cell ratio is an independent prognostic factor in classical Hodgkin lymphoma

References

• Harris NL. Hodgkin's lymphomas: classification, diagnosis, and grading. Semin Hematol 1999;36:220–232.
   PubMed Web of Science ®Google Scholar
• Poppema S, Kaleta J, Hepperle B, et al. Biology of Hodgkin lymphoma. Ann Oncol 1992;3(Suppl. 4):5–8.
   PubMedGoogle Scholar
• Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283–4297.
   PubMed Web of Science ®Google Scholar
• van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed–Sternberg cells: a possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999;154:1685–1691.
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin's disease. Leuk Lymphoma 2000;38:363–371.
   PubMed Web of Science ®Google Scholar
• Peh SC, Kim LH, Poppema S. TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. Am J Surg Pathol 2001;25:925–929.
   PubMed Web of Science ®Google Scholar
• Hedvat CV, Jaffe ES, Qin J, et al. Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays. Mod Pathol 2001;14:1270–1276.
   PubMed Web of Science ®Google Scholar
• Gruss HJ, Pinto A, Duyster J, et al. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997;18:156–163.
   PubMedGoogle Scholar
• Atayar C, Poppema S, Visser L, et al. Cytokine gene expression profile distinguishes CD4+/CD57 + T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts. J Pathol 2006;208:423–430.
   PubMed Web of Science ®Google Scholar
• Diehl V, Stein H, Hummel M, et al. Hodgkin's lymphoma: biology and treatment strategies for primary refractory and relapsed disease. Hematology Am Soc Hematol Educ Program 2003:225–247.
   PubMedGoogle Scholar
• Hahn T, Benekli M, Wong C, et al. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 2005;6:557–566.
   Web of Science ®Google Scholar
• Josting A, Rueffer U, Franfklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280–1286.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Lynch JC, Bociek RG, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002;9:1370–1377.
   Web of Science ®Google Scholar
• Porrata LF, Ristow KM, Habermann TM, et al. Absolute lymphocyte/monocyte ratio at diagnosis and interim positron-emission tomography predict survival in classical Hodgkin lymphoma. J Cancer Ther 2013;4:452–459.
   Google Scholar
• Schreck S, Friebel D, Buettner M, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 2009;27:31–39.
   PubMed Web of Science ®Google Scholar
• Alvaro-Naranjo T, Lejeune M, Salvado-Usach MT, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 2005;46:1581–1591.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362:875–885.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Bacigalupo A, Barosi G, et al. Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica 2009;94:550–565.
   PubMed Web of Science ®Google Scholar
• Santoro A, Bonadonna G, Bonfante V, et al. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 1982;306:770–775.
   PubMed Web of Science ®Google Scholar
• Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.
   PubMed Web of Science ®Google Scholar
• Colonna P, Jais JP, Desablens B, et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol 1996;14:1928–1935.
   PubMed Web of Science ®Google Scholar
• Sup SJ, Alemany CA, Pohlman B, et al. Expression of bcl2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 2005;23:3773–3779.
   PubMed Web of Science ®Google Scholar
• Nadali G, Tavecchia L, Zanolin E, et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998;91: 3011–3016.
   PubMed Web of Science ®Google Scholar
• Reynolds GM, Billingham LJ, Gray LJ, et al. Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of B symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br J Haematol 2002;118: 195–201.
   PubMed Web of Science ®Google Scholar
• Glimelius I, Edstrom A, Amini RM, et al. IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. Eur J Haematol 2006;4:278–283.
   Web of Science ®Google Scholar
• Spector N, Milito CB, Biasoli I, et al. The prognostic value of the expression of bcl2, p53 and LMP1 in patients with Hodgkin's lymphoma. Leuk Lymphoma 2005;9:1301–1306.
   Web of Science ®Google Scholar
• Tzankov A, Krugmann J, Fend F, et al. Prognostic significance of CD20 expression in classical Hodgkin lymhoma: a clinicopathological study of 119 cases. Clin Cancer Res 2003;9:1381–1386.
   PubMed Web of Science ®Google Scholar
• Portlock CS, Donnelly GB, Qin J, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol 2004;125:701–708.
   PubMed Web of Science ®Google Scholar
• Molin D, Edstrom A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 2002;119:122–124.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467–1473.
   PubMed Web of Science ®Google Scholar
• Marshall N, Christie L, Munro L, et al. Immunosuppressive regulatory T-cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755–1762.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression free survival in Hodgkin Lymphoma. Blood 2006;107:52–59.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin lymphoma patients. Ann Oncol 2006;17:1296–1300.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: a report from joint Italian-Danish study. J Clin Oncol 2007;25:3746–3752.
   PubMed Web of Science ®Google Scholar